FIECON at ISPOR EUROPE

17th - 20th November - Barcelona, Spain

HTA 'Fireside Chat'

On Monday, 18th November from 11:20 am to 11:40 am, ISPOR attendees are invited to the FIECON stand (#1201) for our inaugural 'fireside chat' The Evolution of HTA' with health economists and HTA experts - Dawn Lee and Mark Fisher, hosted by Karl Freemyer.

Dawn is a health economic modeller who has conducted over 50 UK Health Technology Assessment submissions and worked in over 30 countries globally. Mark has conducted over 100 health economics and outcomes research projects and led more than 50 pricing and reimbursement submissions across Europe, North and South America, Asia and Australasia.

Come and hear Mark and Dawn discuss their insights on HTA, including JCA, the topic which will be dominating the discussion in Barcelona.

Learn about JCA

Dive into HEOR trending topics

Early value assessment for pipeline optimization

Whether you're considering self-funded launches or out-licensing, our model provides comprehensive simulations of potential benefits, enhancing your strategic decision-making process in commercialization.

Find out more

Joint Clinical Assessment (JCA)

What is JCA? Is my product eligible? The Joint Clinical Assessment (JCA) for oncology, haematology, and ATMPs will be eligible for assessment from January 12th, 2025 with two significant updates this month.

Find out more

PICOS prediction for HTA/payer scoping

We offer an advanced value communication tool that allows you to dynamically create custom scenarios, maximizes the efficiency and guarantees highly engaging meetings with the payers.

Find out more

Market Opportunity in Saudi Arabia

We offer an advanced value communication tool that allows you to dynamically create custom scenarios, maximizes the efficiency and guarantees highly engaging meetings with the payers.

Find out more

Get transparent pricing using our RFP builder!

Input top line project details and select the deliverable of interest and you'll receive a ballpark quote immediately, no commitment necessary! Our RFP Builder is the dawn of a new era in HEOR pricing transparency

Explore our pricing

Rapid scientific advice

We provide fast, flexible, and affordable solutions by asking open-ended questions based on the critique of clinical trial programs and economic models.

Find out more

Our team

A team of FIECON experts will be available to discuss our products and services at stand #1201 in the main exhibition hall.

Mark Fisher

Chief Operating Officer

Talk to Mark about:

HEOR
HTA
Market Access

Karl Freemyer

Head of Business Development

Talk to Karl about:

AI-assisted SLRs
Digital Modelling Dashboards
PICOs Prediction for Joint Clinical Assessment

Susan Suponcic

Strategic Council member

Talk to Susan about:

US and Global Product Launch Strategy
Strategic and Tactical Pricing Initiatives
Portfolio Investment Optimisation

Richard Tolley

Head of Client Partnerships

Talk to Richard about:

Pricing, Reimbursement and Market Access solutions
Value Assessment and Communication
Payer Evidence Strategy

Andrew Revel

Director of Business Development

Talk to Andrew about:

HEOR and Market Access Solutions
Partnership Strategies
Early Value Assessment of Assets

Lawrence Murphy

Director of Business Development

Talk to Lawrence about:

HTA submissions
Early Value Assessments
Joint Clinical Assessment (JCA)

Sabine Gaugris

Executive Director

Talk to Sabine about:

HTA submissions
HEOR and HTA strategy
Joint Clinical Assessment (JCA)

Lisa Cox

Executive Director

Talk to Lisa about:

HTA Strategy
HEOR Strategy
Submission Strategy Advice

Our Research & Posters

We will be presenting on 7 research topics this year, including a an assessment of the application of the NICE Severity Modifier and determining precedents for decision-making and acceptability of evidence in completed National Institute of Health and Care Excellence (NICE) highly specialised technology (HST) appraisals.

Poster presenters will be available in person to talk about their research conclusions during the discussion periods.

Poster Session 1

Date: Monday, 18th November

Poster session time: 10:30AM-1:30PM

Discussion period: 12:30PM-1:30PM

EE144: The Budget Impact of Cangrelor for the Treatment of Patients with Gastric Absorption Issues Undergoing Percutaneous Coronary Intervention in the UK.

Poster Session 2

Date: Monday, 18th November

Poster session time: 4:00PM-7:00PM

Discussion period: 6:00PM-7:00PM

HTA119: Assessing a potential framework to prioritise generalised cost-effectiveness analysis (GCEA) value elements in future decision-making by evidence and relevance: case study across oncology and infectious diseases.

Poster Session 3

Date: Tuesday, 19th November

Poster session time: 10:30AM-1:30PM

Discussion period: 12:30AM-1:30AM

HTA163: An Assessment of the Application of the NICE Severity Modifier.

EE381: Budget Impact of Icosapent Ethyl in Patients with Recent Acute Coronary Syndrome in Catalonia.

HTA198: Precedents for Reimbursed Highly Specialised Technologies Appraised By the National Institute for Health and Care Excellence.

Poster Session 4

Date: Tuesday, 19th November

Poster session time: 4:00PM-7:00PM

Discussion period: 6:00PM-7:00PM

CO131: Comparative efficacy of elafibranor and seladelpar in patients with primary biliary cholangitis: A network meta-analysis.

EE611: Cost-Effectiveness of Icosapent Ethyl in Patients with Recent Acute Coronary Syndrome in Catalonia.

HTA272: Current Guidelines on the Use of Artificial Intelligence in Health Technology Assessments.

Get in touch

Get a completely free, no-obligation opportunity to discuss your needs and see how we can boost your business.

Brainstorm solutions to key challenges with experienced team
Validate your strategy and value evidence
Learn more about FIECON’s products and key areas of expertise and discuss opportunities for collaboration

Thank you!

We received your details. Someone from our team will contact you soon.

Oops!

Something went wrong while submitting the form.

FIECON at ISPOR EUROPE

17th - 20th November - Barcelona, Spain

HTA 'Fireside Chat'

Dive into HEOR trending topics

Early value assessment for pipeline optimization

Joint Clinical Assessment (JCA)

PICOS prediction for HTA/payer scoping

Market Opportunity in Saudi Arabia

Get transparent pricing using our RFP builder!

Rapid scientific advice

Our team

Mark Fisher

Karl Freemyer

Susan Suponcic

Richard Tolley

Andrew Revel

Lawrence Murphy

Sabine Gaugris

Lisa Cox

Our Research & Posters

Poster Session 1

EE144: The Budget Impact of Cangrelor for the Treatment of Patients with Gastric Absorption Issues Undergoing Percutaneous Coronary Intervention in the UK.

Poster Session 2

HTA119: Assessing a potential framework to prioritise generalised cost-effectiveness analysis (GCEA) value elements in future decision-making by evidence and relevance: case study across oncology and infectious diseases.

Poster Session 3

HTA163: An Assessment of the Application of the NICE Severity Modifier.

EE381: Budget Impact of Icosapent Ethyl in Patients with Recent Acute Coronary Syndrome in Catalonia.

HTA198: Precedents for Reimbursed Highly Specialised Technologies Appraised By the National Institute for Health and Care Excellence.

Poster Session 4

CO131: Comparative efficacy of elafibranor and seladelpar in patients with primary biliary cholangitis: A network meta-analysis.

EE611: Cost-Effectiveness of Icosapent Ethyl in Patients with Recent Acute Coronary Syndrome in Catalonia.

HTA272: Current Guidelines on the Use of Artificial Intelligence in Health Technology Assessments.

Get in touch

Your contact details

Thank you!

Oops!

Thank you for your subscription!

Oops...